{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T04:01:23Z","timestamp":1769918483868,"version":"3.49.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["1NU58DP007156"],"award-info":[{"award-number":["1NU58DP007156"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030760","name":"Bayer in The US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030760","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021045","name":"Massachusetts Department of Public Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021045","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.clgc.2025.102372","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T17:27:53Z","timestamp":1746725273000},"page":"102372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Utilization Patterns and Survival in Older Men With Metastatic Prostate Cancer Treated with Radium-223 in the United States: A SEER-Medicare Study"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9440-6295","authenticated-orcid":false,"given":"Bo","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit D.","family":"Raval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nethra","family":"Sambamoorthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Korn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5860-5412","authenticated-orcid":false,"given":"Niculae","family":"Constantinovici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0581-7963","authenticated-orcid":false,"given":"Rana","family":"McKay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usha","family":"Sambamoorthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clgc.2025.102372_bib0001","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.2246","article-title":"Trends in incidence of metastatic prostate cancer in the US","volume":"5","author":"Desai","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clgc.2025.102372_bib0002","unstructured":"CDC. U.S. cancer statistics prostate cancer stat bite. 2024."},{"issue":"22","key":"10.1016\/j.clgc.2025.102372_bib0003","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1001\/jama.291.22.2713","article-title":"Natural history of early, localized prostate cancer","volume":"291","author":"Johansson","year":"2004","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.clgc.2025.102372_bib0004","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration-resistant prostate cancer population: a systematic review","volume":"65","author":"Kirby","year":"2011","journal-title":"Int J Clin Pract"},{"issue":"3","key":"10.1016\/j.clgc.2025.102372_bib0005","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102372_bib0006","article-title":"Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer","volume":"9","author":"O\u2019Sullivan","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"10.1016\/j.clgc.2025.102372_bib0007","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, Version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.clgc.2025.102372_bib0008","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1038\/s41598-020-63302-2","article-title":"Clinical aspects of mCRPC management in patients treated with radium-223","volume":"10","author":"Rizzini","year":"2020","journal-title":"Sci Rep"},{"issue":"6 suppl","key":"10.1016\/j.clgc.2025.102372_bib0009","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1200\/JCO.2020.38.6_suppl.223","article-title":"Real-world utilization of radium-223 (Ra-223) for the treatment of metastatic castration-resistant prostate cancer (mCRPC): a US tertiary oncology center analysis","volume":"38","author":"McKay","year":"2020","journal-title":"J Clinical Oncology"},{"issue":"1","key":"10.1016\/j.clgc.2025.102372_bib0010","doi-asserted-by":"crossref","first-page":"107.e1","DOI":"10.1016\/j.clgc.2022.09.002","article-title":"Real World Outcomes in patients with metastatic, castration-resistant prostate cancer treated with radium-223 in routine clinical practice in sweden","volume":"21","author":"Stattin","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2025.102372_bib0011","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1016\/j.clgc.2017.08.020","article-title":"The contemporary use of radium-223 in metastatic castration-resistant prostate cancer","volume":"16","author":"Heinrich","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2025.102372_bib0012","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41391-020-00271-7","article-title":"Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center","volume":"24","author":"McKay","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"10.1016\/j.clgc.2025.102372_bib0013","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41391-023-00725-8","article-title":"Real-world treatment patterns and overall survival among men with metastatic castration-resistant prostate cancer (mCRPC) in the US medicare population","volume":"27","author":"Freedland","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"10.1016\/j.clgc.2025.102372_bib0014","first-page":"31","article-title":"Understanding and addressing social determinants to advance cancer health equity in the United States: A blueprint for practice, research, and policy","volume":"70","author":"Alcaraz","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.clgc.2025.102372_bib0015","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1186\/s12913-022-08899-y","article-title":"Comparing mental and physical health of U.S. veterans by VA healthcare use: implications for generalizability of research in the VA electronic health records","volume":"22","author":"Fink","year":"2022","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"10.1016\/j.clgc.2025.102372_bib0016","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.clgc.2019.12.019","article-title":"Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States","volume":"18","author":"George","year":"2020","journal-title":"Clin Genitourin Cancer"},{"issue":"10","key":"10.1016\/j.clgc.2025.102372_bib0017","doi-asserted-by":"crossref","first-page":"350","DOI":"10.5489\/cuaj.4415","article-title":"A population-based study of the use of radium 223 in metastatic castration-resistant prostate cancer: factors associated with treatment completion","volume":"11","author":"Parimi","year":"2017","journal-title":"Can Urol Assoc J"},{"issue":"2","key":"10.1016\/j.clgc.2025.102372_bib0018","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/j.clgc.2016.08.015","article-title":"Radium-223 Use in clinical practice and variables associated with completion of therapy","volume":"15","author":"McKay","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2025.102372_bib0019","first-page":"200","article-title":"Imaging and treatment recommendations in patients with castrate-resistant prostate cancer","volume":"19","author":"Albala","year":"2017","journal-title":"Rev Urol"},{"issue":"8","key":"10.1016\/j.clgc.2025.102372_bib0020","first-page":"703","article-title":"Socioeconomic status and breast cancer incidence in California for different race\/ethnic groups","volume":"12","author":"Yost","year":"2001","journal-title":"Cancer Causes and Control"},{"issue":"7","key":"10.1016\/j.clgc.2025.102372_bib0021","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/gerona\/glx229","article-title":"Measuring frailty in medicare data: development and validation of a claims-based frailty index","volume":"73","author":"Kim","year":"2018","journal-title":"J Gerontol : Series A"},{"issue":"5","key":"10.1016\/j.clgc.2025.102372_bib0022","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/pros.23286","article-title":"Clinical correlates of benefit from radium-223 therapy in metastatic castration resistant prostate cancer","volume":"77","author":"Alva","year":"2017","journal-title":"Prostate."},{"issue":"2","key":"10.1016\/j.clgc.2025.102372_bib0023","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41391-021-00488-0","article-title":"Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)","volume":"25","author":"George","year":"2022","journal-title":"Prost Cancer Prostatic Dis"},{"issue":"5","key":"10.1016\/j.clgc.2025.102372_bib0024","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/UPJ.0000000000000316","article-title":"Radium-223 utilization patterns and outcomes in clinical practice","volume":"9","author":"Taich","year":"2022","journal-title":"Urol Pract"},{"issue":"9","key":"10.1016\/j.clgc.2025.102372_bib0025","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.clon.2018.06.004","article-title":"Real-world outcomes and factors predicting survival and completion of radium 223 in metastatic castrate-resistant prostate cancer","volume":"30","author":"Parikh","year":"2018","journal-title":"Clin Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102372_bib0026","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s13139-022-00760-8","article-title":"Outcomes and factors associated with completion of radium-223 therapy","volume":"56","author":"Liu","year":"2022","journal-title":"Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.clgc.2025.102372_bib0027","doi-asserted-by":"crossref","first-page":"64.e1","DOI":"10.1016\/j.urolonc.2021.11.005","article-title":"Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: a real-world multicenter retrospective study","volume":"40","author":"Sasaki","year":"2022","journal-title":"Urol Oncol"},{"issue":"5_suppl","key":"10.1016\/j.clgc.2025.102372_bib0028","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1200\/JCO.2025.43.5_suppl.81","article-title":"Effectiveness and safety of radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC): a systematic literature review of 48 real-world studies","volume":"43","author":"Lunan","year":"2025","journal-title":"J Clin Oncol"},{"issue":"61","key":"10.1016\/j.clgc.2025.102372_bib0029","first-page":"77","article-title":"Real-World utilization patterns of radium-223 in metastatic prostate cancer in the united states: an administrative claims database study","volume":"68","author":"Raval","year":"2024","journal-title":"Age"},{"issue":"1","key":"10.1016\/j.clgc.2025.102372_bib0030","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s12885-018-4166-3","article-title":"Temporal and geographic variation in the systemic treatment of advanced prostate cancer","volume":"18","author":"Caram","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clgc.2025.102372_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1385466","article-title":"Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer","volume":"14","author":"Anido-Herranz","year":"2024","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102372_bib0032","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/MNM.0000000000001325","article-title":"Radium-223 therapy for metastatic castration-resistant prostate cancer: survival benefit when used earlier in the treatment pathway","volume":"42","author":"Jarvis","year":"2021","journal-title":"Nuclear Med Commun"},{"issue":"1","key":"10.1016\/j.clgc.2025.102372_bib0033","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1634\/theoncologist.2019-0338","article-title":"Use of high-cost cancer treatments in academic and nonacademic practice","volume":"25","author":"Mitchell","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2025.102372_bib0034","doi-asserted-by":"crossref","first-page":"S1254","DOI":"10.1016\/j.annonc.2024.08.2307","volume":"35","author":"Gillessen","year":"2024","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2025.102372_bib0035","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40291-022-00594-2","article-title":"Lutetium Lu 177 Vipivotide Tetraxetan: first approval","volume":"26","author":"Keam","year":"2022","journal-title":"Mol Diagn Ther"},{"issue":"18","key":"10.1016\/j.clgc.2025.102372_bib0036","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.clgc.2025.102372_bib0037","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1200\/JCO.23.02182","article-title":"US Food and Drug Administration approval summary: Talazoparib in combination with enzalutamide for treatment of patients with homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer","volume":"42","author":"Heiss","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102372_bib0038","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.e15148","article-title":"Bone metastasis (BM) based on SEER registry versus Medicare claims among metastatic prostate cancer (PCa) patients (pts) in SEER-Medicare","volume":"30","author":"Onukwugha","year":"2012","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clgc.2025.102372_bib0039","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1097\/MLR.0000000000000539","article-title":"Accuracy of Medicare Claim\u2013based Algorithm to Detect Breast, Prostate, or Lung Cancer Bone Metastases","volume":"55","author":"Sathiakumar","year":"2017","journal-title":"Medical Care"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000734?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000734?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:06:32Z","timestamp":1762596392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325000734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1558767325000734"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102372","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilization Patterns and Survival in Older Men With Metastatic Prostate Cancer Treated with Radium-223 in the United States: A SEER-Medicare Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102372","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102372"}}